A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Ribociclib
Related studies linked through entity extraction aliases.
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Status
- RECRUITING
- Phase
- PHASE3
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt
- Status
- COMPLETED
- Phase
- PHASE4
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Status
- RECRUITING
- Phase
- PHASE3
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
- Status
- RECRUITING
- Phase
- N/A
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
- Status
- RECRUITING
- Phase
- N/A
Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- Status
- RECRUITING
- Phase
- N/A
RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia
- Status
- RECRUITING
- Phase
- N/A
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Status
- RECRUITING
- Phase
- PHASE3